The estimated Net Worth of Peter C Richardson is at least $279 millier dollars as of 14 January 2010. Peter Richardson owns over 22,717 units of Mallinckrodt Plc stock worth over $41,649 and over the last 19 years Peter sold MNK stock worth over $237,562.
Peter has made over 2 trades of the Mallinckrodt Plc stock since 2009, according to the Form 4 filled with the SEC. Most recently Peter sold 22,717 units of MNK stock worth $227,170 on 14 January 2010.
The largest trade Peter's ever made was selling 22,717 units of Mallinckrodt Plc stock on 14 January 2010 worth over $227,170. On average, Peter trades about 962 units every 6 days since 2005. As of 14 January 2010 Peter still owns at least 122,497 units of Mallinckrodt Plc stock.
You can see the complete history of Peter Richardson stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is 675 MCDONNELL BLVD., , HAZELWOOD, MO, 63042.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... et Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: